GeneTex, Inc.
IRVINE, CA / ACCESSWIRE / June 6, 2023 / GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclonal antibody for immunohistochemistry (IHC).
The interaction between PD-L1 (CD274/B7-H1) and its receptor programmed death-1 (PD-1) is not only a focus of cancer immunotherapy research but also has major therapeutic relevance for many solid malignancies. PD-L1 is an immune checkpoint inhibitor that binds to PD-1 expressed on T cells and other effectors to quash immune system overactivation and autoimmunity. Cancer cells exploit this and overexpress PD-L1, creating an immunosuppressive state through induced cell death of anti-tumor T cells. Thus, gauging PD-L1 expression on tumor cells can identify cancers that may respond to anti-PD-L1/PD-1 agents. Given the importance of PD-L1 detection in patient tumor samples for both prognostic and treatment considerations, reliable reagents are clearly essential for both research and clinical decision-making.
Immunohistochemistry is utilized routinely in both academic and clinical settings to determine PD-L1 expression in both normal and cancerous tissues. GeneTex's recombinant rabbit monoclonal antibody (PD-L1 antibody [HL1041]) is a cited, PD-L1-specific, knockout-validated reagent that performs in three applications (i.e., western blot, immunocytochemistry, and IHC). To further evaluate this antibody's IHC capabilities, GeneTex enlisted the assistance of MS Validated Antibodies GmbH (MSVA), a company with demonstrated proficiency in IHC optimization that has assessed over 5000 antibodies for their functionality in formalin-fixed tissue IHC. MSVA completed an extensive analysis of the GeneTex antibody's staining on tumor samples and a broad array of normal tissues, comparing the signal to that of another well-established PD-L1 antibody (see Figure). GeneTex clone [HL1041] exhibited excellent sensitivity and specificity. Marco Sauter, MSVA CEO, commented, "As formalin fixation alters the structure and accessibility of many epitopes, a trustworthy antibody validation for IHC invariably requires the analysis of a very broad range of formalin-fixed tissues. Our analysis of more than 70 different normal tissue types and of a broad range of different cancers exceeds what regulatory agencies currently require. We are gratified that our MSVA approach could help to identify PD-L1 clone [HL1041] with binding properties that are comparable to the most established PD-L1 antibodies on the market."
The need for quality antibodies to visualize the expression of biomarkers crucial for cancer biology research and patient care remains vast, particularly for IHC. GeneTex is presently developing reagents against a number of key targets. Allen Lee, GeneTex's Vice President of Business Development, stressed the importance of expertise-based collaborations to create gold-standard products for scientists and clinicians: "GeneTex is excited to extend our partnership with MSVA. Their IHC validation services align perfectly with GeneTex's core mission, which is to provide the biomedical community with the highest quality immunological reagents supported by extensive research, development, and validation."
GeneTex products are for research use only. Not for diagnostic or therapeutic procedures.
Media Contact:
Allen Lee
Phone: 949.553.1900
Email: allensl@genetex.com
www.genetex.com
Contact Information
Allen Lee
Vice President - Business Development
allensl@genetex.com
(949)553-1900
SOURCE: GeneTex, Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/759287/GeneTex-Launches-PD-L1-Antibody-Comprehensively-Validated-by-MS-Validated-Antibodies-GmbH-for-Immunohistochemistry
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs Achieves Milestone Fifth Consecutive ISO 27001 Certification, Reinforcing World-Class Security and Privacy Commitment20.1.2026 09:00:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / January 20, 2026 / Sauce Labs, the leading provider of Continuous Testing and Cloud-based Software Quality solutions, today announced the successful renewal of its critical ISO/IEC 27001:2022 and ISO 27701:2019 certifications. This achievement marks the fifth consecutive year for the ISO/IEC 27001 (Information Security Management System) and the fourth consecutive year for the ISO 27701 (Privacy Information Management System), solidifying the company's position as a trusted partner for global enterprises. The rigorous, independent audit confirmed Sauce Labs' systematic and robust approach to managing sensitive information and personal data, resulting in zero Minor or Major Nonconformities. "Reaching this five-year milestone with zero nonconformities is a massive validation of our ongoing investment in security and compliance," said Marcia Foley, VP of Global Compliance at Sauce Labs. "For our customers, this renewal is undeniable proof that Sauce L
IXOPAY Launches New TokenEx Packages, Setting the Standard for Token-First Payments in the Era of Agentic Commerce20.1.2026 06:00:00 CET | Press release
New TokenEx packages give merchants a faster, clearer path to secure and independent payments. In parallel, IXOPAY expands its global payments capabilities with new support for Brazil's PIX instant payment system. LEHI, UTAH / ACCESS Newswire / January 20, 2026 / IXOPAY, the enterprise-grade global payment infrastructure platform built for the era of agentic commerce, today announced the launch of three new TokenEx tokenization packages designed to help merchants secure payment data, reduce complexity, and maintain independence across processors, markets, and payment methods. As payments ecosystems become increasingly fragmented, many businesses remain constrained by processor-owned tokens, rigid integrations, and infrastructure that is costly to change. IXOPAY's new TokenEx packages establish tokenization as the foundation for modern payments, giving merchants a standardized, future-ready way to protect data, retain control, and scale without re-architecting their payments stack. "Tok
RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units20.1.2026 00:00:00 CET | Press release
All amounts in Canadian dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce that, as part of the Company's annual compensation review, the Board of Directors have authorized the grant of 1,195,000 stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options have an exercise price of CAD $0.30 per share and are exercisable for a period of three-years from the date of grant. The Options were granted in accordance with the Company's Stock Option Plan. In addition, the Board of Directors have authorized the grant of an aggregate 800,000 restricted share units ("RSUs") to officers, employees and consultants of the Company. The RSUs were granted in accordance with the Company's RSU Plan in place. "We are pleased to provide these incentive-based equity awards to our valued team members," said Bernard Tan, CEO
GA-ASI and Barzan Holdings Sign MOU19.1.2026 18:00:00 CET | Press release
Companies Will Collaborate on the Development of Advanced Battle Management DOHA, QA / ACCESS Newswire / January 19, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) -- the world leader in unmanned systems - and Barzan Holdings, Qatar's national defence and security leader, signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced Battle Management software capabilities. The signing took place on Monday during the Doha International Maritime Defence Exhibition and Conference (DIMDEX). The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Barzan Holdings to develop software solutions that enhance theater-level situational awareness and enable the efficient processing, correlation, and dissemination of intelligence. These capabilities are intended to support faster, higher-quality decision-making in complex, multi-domain operational environments. For General Atomics, the agreement underscores the strategic importance of
GA-ASI Makes Another Autonomous Aerial Intercept in Company-Funded Demo with MQ-20 Avenger(R)19.1.2026 03:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 18, 2026 / In its latest demonstration of advanced autonomy development, General Atomics Aeronautical Systems, Inc. (GA-ASI) successfully executed a mission autonomy flight using its MQ-20 Avenger® jet equipped with the latest government reference autonomy software. The test included a live engagement between the MQ-20 and an aggressor aircraft flown by an onboard human pilot, highlighting the advanced maturity of autonomous systems, seamless integration of mission elements, and the ability of autonomy to leverage onboard sensors to make independent decisions and execute complex tasks. GA-ASI's Avenger jet has served as a surrogate for Collaborative Combat Aircraft (CCA) for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft. The recent Avenger demo began with planning in the Human-Machine Interface (HMI), followed by loading the mission profile onto the MQ-20. Once airborne, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom